ATRC logo

AtriCure, Inc. Stock Price

NasdaqGM:ATRC Community·US$1.8b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

ATRC Share Price Performance

US$36.18
8.58 (31.09%)
39.7% undervalued intrinsic discount
US$60.00
Fair Value
US$36.18
8.58 (31.09%)
39.7% undervalued intrinsic discount
US$60.00
Fair Value
Price US$36.18
AnalystHighTarget US$60.00
AnalystConsensusTarget US$50.00
AnalystLowTarget US$40.00

ATRC Community Narratives

AnalystHighTarget·
Fair Value US$60 41.5% undervalued intrinsic discount

Aging And Chronic Diseases Will Boost Minimally Invasive Cardiac Solutions

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$50 29.8% undervalued intrinsic discount

Minimally Invasive Procedures Will Expand Global Markets

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AnalystLowTarget·
Fair Value US$40 12.3% undervalued intrinsic discount

Global Cardiac Ablation Market Will Face Intensified Challenges Yet Rebound

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent ATRC News & Updates

AtriCure, Inc. (NASDAQ:ATRC) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 01
AtriCure, Inc. (NASDAQ:ATRC) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry?

Jul 08
AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry?

AtriCure: Profits And Operating Leverage Are Needed Here

Jun 26

AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch

May 01
AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch

AtriCure, Inc. Key Details

US$499.9m

Revenue

US$126.4m

Cost of Revenue

US$373.5m

Gross Profit

US$409.9m

Other Expenses

-US$36.4m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 29, 2025
Earnings per share (EPS)
-0.73
Gross Margin
74.71%
Net Profit Margin
-7.27%
Debt/Equity Ratio
13.3%

AtriCure, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

1 Risk
2 Rewards

About ATRC

Founded
2000
Employees
1300
CEO
Michael Carrel
WebsiteView website
www.atricure.com

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula’s to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 5.1%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a loss of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›